More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached ...

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...

Novartis ( (NVS) ) has provided an update. Novartis announced the success of its Phase III STEER study for investigational ...

The results from the Phase III STEER study add to the clinical data and emerging real-world evidence for the use of one-time ...

The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...

Novartis’ Phase III study has demonstrated significant improvement in motor function in children and young adults with spinal ...

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma ...

Basel: Novartis has announced positive topline results from the Phase III STEER study. This pivotal study assessed the ...